#1BIONTECH 4th Quarter & Full Year 2021 Financial Results & Corporate Update March 30, 2022 COVID-19 BIONTECH 1 WINDO HDFINO12 INS#2This Slide Presentation Includes Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATYⓇ where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech's initial sales to national governments; the extent to which initial or booster doses of a COVID-19 vaccine continue to be necessary in the future; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; the initiation, timing, progress, results, and cost of BioNTech's research and development programs and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and BioNTech's research and development programs; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); the ability of BNT 162b2 to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioN Tech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of BioNTech's COVID-19 vaccine and other products and product candidates developed or manufactured by us; BioNTech's ability to progress BioNTech's Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature of the collaboration with the African Union and the Africa CDC; the nature and duration of support from WHO, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent and the nature and feasibility of these solutions; BioNTech's estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, shares outstanding; BioNTech's ability and that of BioNTech's collaborators to commercialize and market BioNTech's product candidates, if approved, including BioNTech's COVID-19 vaccine; BioNTech's ability to manage BioNTech's development and expansion; regulatory developments in the United States and foreign countries; BioNTech's ability to effectively scale BioNTech's production capabilities and manufacture BioNTech's products, including BioNTech's target COVID-19 vaccine production levels, and BioNTech's product candidates; and other factors not known to BioNTech at this time. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward- looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's annual report on Form 20-F for the quarter and year ended December 31, 2021 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. 2 BIONTECH#3Safety Information COMIRNATYⓇ (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorization (CMA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 5 years of age. The vaccine is administered as a 2-dose series, 3 weeks apart. In addition, the CMA has been expanded to include a booster dose (third dose) at least 6 months after the second dose in individuals 18 years of age and older. For immunocompromised individuals, the third dose may be given at least 28 days after the second dose. The European Medicines Agency's (EMA's) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available. IMPORTANT SAFETY INFORMATION: Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine. Very rare cases of myocarditis and pericarditis have been observed following vaccination with Comirnaty. These cases have primarily occurred within 14 days following vaccination, more often after the second vaccination, and more often in younger men. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting. The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY® may be lower in immunosuppressed individuals. As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine. In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (>10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age. The overall safety profile of COMIRNATY® in participants 5 to 15 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in children 5 to 11 years of age were injection site pain (>80%), fatigue (>50%), headache (>30%), injection site redness and swelling (>20%), myalgia and chills (>10%). The most frequent adverse reactions in clinical trial participants 12 to 15 years of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (>40%), arthralgia and pyrexia (> 20%). There is limited experience with use of COMIRNATY® in pregnant women. Administration of COMIRNATY® in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus. It is unknown whether COMIRNATY® is excreted in human milk. Interactions with other medicinal products or concomitant administration of COMIRNATYⓇ with other vaccines has not been studied. For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website. ● . ● ● ● ● ● The black equilateral triangle ▼ denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email [email protected], telephone +49 6131 9084 0, or via the website www.biontech.de 3 2 Pfizer BIONTECH#4Safety Information AUTHORIZED USE IN THE U.S. COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. It is also authorized under EUA to provide a 2-dose primary series to individuals 5 years of age and older, a third primary series dose to individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise, a single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY®, a single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine, a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized COVID-19 vaccine; and a second booster dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series. IMPORTANT SAFETY INFORMATION Individuals should not get the vaccine if they: had a severe allergic reaction after a previous dose of this vaccine had a severe allergic reaction to any ingredient of this vaccine ● Individuals should tell the vaccination provider about all of their medical conditions, including if they: have any allergies have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) have a fever ● ● . • have a bleeding disorder or are on a blood thinner are immunocompromised or are on a medicine that affects the immune system are pregnant, plan to become pregnant, or are breastfeeding I have received another COVID-19 vaccine have ever fainted in association with an injection The vaccine may not protect everyone. Side effects reported with the vaccine include: There is a remote chance that the vaccine could cause a severe allergic reaction O A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination O Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness O If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine, more commonly in males under 40 years of age than among females and older males. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine: O chest pain O shortness of breath O feelings of having a fast-beating, fluttering, or pounding heart Additional side effects that have been reported with the vaccine include: O severe allergic reactions; non-severe allergic reactions such as rash, itching, hives, or swelling of the face; myocarditis (inflammation of the heart muscle); pericarditis (inflammation of the lining outside the heart); injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); decreased appetite; diarrhea; vomiting; arm pain; fainting in association with injection of the vaccine These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away 2Pfizer Data on administration of this vaccine at the same time as other vaccines have not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines should discuss their options with their healthcare provider. Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafety reporting.com or by calling 1-800-438-1985. BIONTECH#55 Agenda 01 Fourth Quarter and Full Year 2021 Highlights Ugur Sahin, 02 COVID-19 Vaccine Update Özlem Türeci, CMO 03 Oncology Pipeline Update Özlem Türeci, 04 Financial Results Jens Holstein, CFO 05 Corporate Outlook Ryan Richardson, Chief Strategy Officer BIONTECH#6Our Vision: Harnessing The Power Of The Immune System To Fight Human Diseases 6 |||| !!! Fully Integrated Biotechnology Company Multi-Platform, Technology Agnostic Strategy Global Social Responsibility Focus on high medical needs ● Democratize access to novel medicines K D ARA Diversified Product Pipeline Immunotherapy Powerhouse expanding the therapeutic universe BIONTECH#72021 Key Highlights of Progress Towards Vision COVID-19 VACCINE ~2.6 Bn doses delivered GLOBAL LEADERSHIP in 2021 7 e Multiple randomized Phase 2 trials 2 Fix Vac programs 2 iNeST programs 1 Bispecific Immunomodulator ● to DROVE ADVANCEMENT IN ONCOLOGY New platforms entered the clinic RiboCytokines RiboMabs CAR-T cell therapy NEOSTIM individualized neoantigen T cell therapy EXPANDED GLOBAL ORGANIZATION 3,000+ team members Increased footprint with new offices in U.S., Europe and Asia > 165 countries & territories ¹ ● ● ● >1 Bn to low- and middle- income countries ¹ Strategic M&A to complement existing technologies Acquired Kite's cell therapy facility in U.S. Kite asset acquisition expanded personalized TCR platform Expanded TCR pipeline with Medigene asset acquisition and research collaboration STRONG FINANCIAL PERFORMANCE €19.0 Bn Total 2021 Revenues² 1 As of end 2021 2 Estimated figures based on preliminary data shared between Pfizer and BioNTech as further described in our Annual Report on Form 20-F for the year ending December 31, 2021 €39.63 Diluted EPS² BIONTECH#8Multi-platform Strategy | Technology Agnostic Innovation Engine RIBOLYSINS Precision Antibacterials (Phagomed) INDIVIDUALIZED mRNA CANCER 8 ● VACCINES iNeST INFECTIOUS DISEASES VACCINES Prophylactic vaccines internal technology acquisition collaboration digital & Al capability Therapeutic vaccines OFF-THE-SHELF mRNA CANCER VACCINES Fix Vac mRNA TECHNOLOGY ARTIFICIAL INTELLIGENCE mRNA Drug Design Early SARS-CoV-2 variant detection *mRNA encoded cancer-targeting antibodies and Cytokines RIBOLOGICALS* RiboCytokines RiboMabs ● ● Strengthening platform with collaborations and strategic M&A ● CARVac mRNA Vaccine boosted CAR-T cells PERSONALIZED TCR THERAPY KITE Asset Acquisition MULTI-TARGET TCR RESEARCH COLLABORATION (Medigene) CELL & GENE THERAPIES INDIVIDUALIZED NEOANTIGEN T CELL THERAPY mRNA ENCODED HUMABODIES (Crescendo) SOLID TUMOR CAR-T • Ideal CAR-T cell targets NEXT GEN IMMUNO- MODULATORS Bispecific antibodies ANTIBODIES SMALL MOLECULES TARGETED CANCER THERAPIES SELECTIVE TLR-7 ANTAGONISM BIONTECH#92022 Strategic Priorities ● ● Continue COVID-19 Vaccine Leadership 9 0-0 Label & geographic expansion Next-generation vaccines Innovations for pandemic preparedness ● ● ● Execute in Oncology First randomized Phase 2 readout Prepare for registrational trials POC data for CAR-T cell therapy ● POC, proof of concept; FIH, first-in-human; HSV 2, herpes simplex virus type 2 ● Expand in Infectious Disease Initiate 4 FIH vaccine trials: Shingles HSV 2 Tuberculosis Malaria ● ● ● ● 10+ additional mRNA vaccine programs Precision antibacterials Advance into New Therapeutic Areas ● ● ● III Autoimmune disease Regenerative medicine. Cardiovascular disease Invest in Foundation to Enable Accelerated Innovation and Expansion Digital & Al Capabilities | Technologies | Development Team | Manufacturing | Global Footprint BIONTECH#10Global Social Responsibility at Our Core COVID-19 vaccine pledge to COVAX and the world • 2+ bn doses to low- and middle-income countries by end of 2022 Pandemic response and access to medicines Democratize Access to Novel Medicine Address high medical need diseases such as: Malaria Tuberculosis ● Launched BioNTainers as modular mRNA manufacturing facilities • Establishment of first mRNA manufacturing facility in African Union is expected to start in mid-2022 Introduce drone vaccine delivery in Ghana 10 SBTI, Science Based Targets initiative (in line with Paris agreement) 1 base year: 2021 2 encompasses adhering to ten principles on human rights, the environment and anti-corruption my ¶¶PP Environmental & Climate Protection Climate targets under SBTi Scope 1 & 2: absolute emission reduction of 42% by 20301 ● Responsible Governance Practice good corporate governance and social and societal responsibility Signed UN Global Compact² Attractive Employer Strengthen recruiting and development Diversified employee base from 60+ countries BIONTECH#1111 Agenda 01 02 COVID-19 Vaccine Update Özlem Türeci, CMO Fourth Quarter and Full Year 2021 Highlights Ugur Sahin, CEO 03 Oncology Pipeline Update 04 Financial Results Jens Holstein, CFO 05 Corporate Outlook Ryan Richardson, Chief Strategy Officer BIONTECH#12COVID-19 Vaccine Continued Success in 2022 2022 Order Book as of mid-March: 2.4Bn Doses Continued Label Expansion Global Manufacturing Network Preemptive Approach to Variants 12 Pediatrics • 5 to <12 yrs: ● ● Accomplishments Position Company for ● ● 6 mo to <5 yrs: Evaluating 3-dose regimen; data expected in April 2022 Data will be submitted to FDA and other regulators Obtained approvals in multiple markets¹ for 2-dose regimen for BNT 162b2 Evaluating third dose. ● Comprehensive variant-based vaccine development program Development of Omicron-based vaccine on track • Scaled up manufacturing and started production Boosters Obtained approvals in multiple markets¹ for BNT162b2 booster (3rd dose) in 12 yrs+ Building state-of-the-art mRNA manufacturing sites in Africa and Asia • BioN Tainers designed to enable rapid setup of new mRNA vaccine manufacturing nodes 1 Includes U.S., EU, Canada and other countries FDA approved 4th dose in 50 yrs+ and in 12 yrs+ with certain kinds of immunocompromise Evaluating 3rd or 4th dose of variant-based versus wild-type vaccines Generating clinical data to support potential regulatory submission; first data expected in April 2022 Comprehensive research program to investigate evolution of SARS-CoV-2 directed immunity under vaccinations and infections to inform further vaccine development InstaDeep collaboration to further develop early-warning system for high-risk variants BIONTECH#13Need for Pandemic Vaccination Continues Global Vaccination Status ¹ Unvaccinated 36% (2.86 bn) 13 ■ 1 shot 1 shot 6% (0.46 bn) 2 shots 39% (3.08 bn) 3+ shots 19% (1.50 bn) ■2 shots 3 or more shots ■ Unvaccinated -36% of the world population remains completely unvaccinated. Only 19% of the world population has received a booster vaccination (3+ shots) ● ● Global Confirmed COVID-19 Cases² 10.5 bn Week of February 28 11.6 bn Week of March 7 1 New York Times COVID-19 Vaccination Tracker, as of March 22, 2022 2 World Health Organization COVID-19 Dashboard, as of March 25, 2022 3 The Centre for the Mathematical Modelling of Infectious Diseases at the London School of Hygiene & Tropical Medicine, as of March 22, 2022 12.6 bn Week of March 14 Infection rates remain high, driven by Omicron variant Global weekly infection rate in March 2022 is >170% higher than global weekly infection rate in Q4 2021 54 countries reported an R, >1 3 12 countries with cases doubling (or more) every week³ BIONTECH#14BNT162b2 Boosters to Address Partial Immune Escape by Omicron Israel real-world data suggest a 4th dose increases immunogenicity and lowers rates of confirmed infections and severe illness in elderly population ⁹ BNT162b2 3rd dose required to reinstall immunity and effectiveness against Omicron ¹ 14 ● ● Overall infections (~70-80%)¹-4 Symptomatic disease (~50-85%)1-5 Hospitalizations (~75-90%)2-6 However: Vaccine effectiveness against Omicron starts waning after the first few months post booster7,8 ● Monitoring of emerging variants In subjects >60 years of age, confirmed infection and severe disease after 4th dose¹ was lower compared to individuals who did not receive 4th dose⁹ At 12 days+ post 4th dose, reduced risk was demonstrated compared to only 3 doses 9: Infection by a factor of 2.0 (95% CI 2.0 to 2.1) Severe disease by a factor of 4.3 (95% CI 2.2 to 7.5) Future pandemic preparedness: Rapid data-guided vaccine adaptation 1 Collie SH, et al. N Engl J Med 2022; 386:494-496 DOI: 10.1056/NEJMC2119270; 2 UK Health Security Agency. COVID-19 Vaccine Surveillance Report - Week 8. 24 February 2022; 3 Tartof SY, et al. Available at SSRN: https://ssrn.com/abstract=4011905; 4 Hansen CH, et al. MedRXiv. doi: https://doi.org/10.1101/2021.12.20.21267966; 5 Thompson MG, et al. MMWR Morb Mortal Wkly Rep 2022;71:139-145. DOI: http://dx.doi.org/10.15585/mmwr.mm 7104e3external icon; 6 Lauring AS, et al. BMJ 2022; 376 doi: https://doi.org/10.1136/bmj-2021-069761; 7 Andrews N, et al. NEJM 2022. DOI: 10.1056/NEJMoa2119451; 8 Ferdinands JM, et al. MMWR Morb Mortal Wkly Rep 2022;71:255-263. DOI: http://dx.doi.org/10.15585/mmwr.mm 7107e2external icon; 9 Bar-On YM, et al MedRxiv [Preprint] https://doi.org/10.1101/2022.02.01.22270232. BIONTECH#15Need for Vaccine-Adaptation to Omicron and Potentially Future Emerging Variants Omicron comprises almost 100% of sequenced genomes in most parts of the world ¹ New variants more likely to arise from variants that cause high infection rates 2,3 Real-world data suggest that vaccine-induced immunity provides a higher degree of protection than natural immunity4 As natural immunity wanes, vaccination extends protection against reinfection 6-12 15 Share of Omicron variant in all analyzed sequences in preceeding 2 weeks No data 0% 10% 20% 30% 40% 50% 60% 70% 80% Annual and/or seasonal boosters with variant adapted vaccines expected for the foreseeable future for pandemic preparedness ¹3 13 1 Our World in Data. https://ourworldindata.org/grapher/covid-cases-omicron?country=GBR-FRA-BEL-DEU-ITA-ESP-USA-ZAF~BWA-AUS. Accessed 28/3/22; 2 Atlani-Duault L et al Lancet Public Health 6:e199- e200; DOI:https://doi.org/10.1016/S2468-2667 (21)00036-0; 3 Otto SP, et al. Curr Biol, 2021; 31(14): R918-R929; 4 Shapira G, et al. Faseba 2022; 4: e22223. doi: 10.1096/fj.202101492R; 5 CDC https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html. Accessed 28/3/22; 6 MRC Centre for Global infectious Disease Analysis Report 49 https://www.imperial.ac.uk/mrc- global-infectious-disease-analysis/covid-19/report-49-Omicron; 7 Hammerman A, et al. NEJM 2022; DOI: 10.1056/NEJMoa2119497; 5; 8 Yu, Y et al. Sci Rep 12, 2628 (2022) https://doi.org/10.1038/s41598-022-06629-2; 9 Lombardi A, et al. Journ Infect Pub Health 2021; 14(8): 1120-1122; 7; 10 Mayo Clinic. https://www.mayoclinic.org/diseases- conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808.. Accessed 22 March 2022; 11 Abu-Raddad et IEClinicalMedicine 2021 May;35:100861. doi: 10.1016/j.eclinm.2021.100861. Epub 2021 Apr 28; 12 MRC Centre for Global infectious Disease Analysis Report 49 https://http://www.imperial.ac.uk/m rc-global-infectious-disease-analysis/covid-19/report-49-Omicron/ 6. Accessed 28/3/22; 13 Elliott P, et al [Preprint] https://spiral.imperial.ac.uk/handle/10044/1/93887 World 90% 100% BIONTECH#16Clinical Program to Assess Safety, Tolerability and Immunogenicity of an Omicron-Adapted Vaccine Evaluating different Omicron monovalent vaccine regimens N-1500, 18-55 years and >55 years Vaccine experienced and naïve subjects 1 ● 16 Omicron-based vaccine to to - to toto 3rd dose or 3rd+4th dose BNT162b2 ● ● 2 BNT162b2 4th dose to to to Omicron-based vaccine Evaluating bivalent and combination of Omicron-based vaccine and BNT162b2 N-650, >55 years Two dosages: 30 ug and 60 µg mml=0 30 mg or 60 mg 3 3-dose primary regimen 1 BioNTech. Available at: https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-evaluate-omicron-based-covid. Accessed January 2022; 2 Clinical Trials.gov. Available at: https://www.clinical trials.gov/ct2/show/NCT04955626. Accessed March 2022. Omicron-based vaccine to toto Vaccine naïve subjects BIONTECH#1717 Agenda 01 02 COVID-19 Vaccine Update Özlem Türeci, CMO Fourth Quarter and Full Year 2021 Highlights Ugur Sahin, CEO 03 Oncology Pipeline Update Özlem Türeci, 04 Financial Results Jens Holstein, CFO 05 Corporate Outlook Ryan Richardson, Chief Strategy Officer BIONTECH#18Strong Clinical Execution in Oncology in 2021¹ Data Updates Q4 2021 E 4 Randomized Phase 2 Trial Starts 18 5 First-in-human Phase 1 Trial Starts SITC 2021 ✓BNT111 Phase 1 ✓BNT112 Phase 1/2 BNT211 Phase 1/2 ✓ BNT111 -R/R Melanoma³ BNT113 - HPV16+ HNSCC ✓ BNT211 - CARVac BNT221 - NEOSTIM BNT151 - RiboCytokines R/R, refractory/relapsed; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; FPD, first patient dosed; 1 Includes updates through March 30, 2022; 2 BNT311 (Gen1046) and BNT312 (Gen1042) are partnered with Genmab; 3 Partnered with Regeneron; 4 Autogene Cevumeran is partnered with Genentech BNT3112 Phase 1/2 BNT3122 Phase 1/2 BNT411 Phase 1/2 ESMO-10 2021 BNT211 Phase 1/2 Milestone achieved in full year 2021 Autogene Cevumeran4 (BNT122) - Adjuvant colorectal cancer BNT311-R/R NSCLC - FPD Dec 2021 ✔BNT152+153 - RiboCytokines BNT141 - RiboMabs - FPD Jan 2022 Milestone achieved in Q4 2021 and early 2022 BIONTECH#19BNT311 Phase 1/2: First-in-Human Study of DuoBody-PD-L1x4-1BB Next Generation Immunomodulator designed to prime and activate anti-tumor T cell and NK cell function via Mechanism of action of FC-silenced DuoBody-PD-L1x4-1BB T Cell PD-L1 blockade and Conditional 4-1 BB stimulation 19 TCR 4-1BB MHC-1/11 PD-L1* (tumor cell/APC) PD-1 DuoBody-PD-L1x4-188 PD-L1 DuoBody-PD-L1x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage LOCAL LYMPH NODES NK TUMOR SITC 2021 Peripheral and Tumoral Immunologic Responses Supportive of Proposed Mechanism of Action in CPI-experienced NSCLC Patients ● ● Program partnered with Genmab; 50:50 profit/loss NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; NK cell, natural killer cell; CPI, checkpoint inhibitor PD-L1 Inhibitor-Pre-treated patients 25 NSCLC patients with evaluable baseline tumors Best relative change in sum of diameters from baseline, % ● 40 20 -20- -40- -60- Im PD-L1+ PD-L1- Patients with tumor reduction mainly PD-L1+ tumors Tumor reduction in 7 of 11 patients with PD-L1+ tumors Patient selection by PD-L1 status and combination with anti-PD-L1 may improve efficacy of BNT311 BIONTECH Y#20BNT311: Phase 2 Trial Targeting CPI-experienced PD-L1+ R/R NSCLC ● ***** Stage IV metastatic R/R NSCLC (2L+) PD-L1 TPS ≥1% 20 R FPD in December 2021 N-130 Primary Endpoints 1:1:1 ORR per RECIST 1.1 Standard of Care Benchmark 2 Docetaxel, ORR: 4-15% ² A: BNT311 monotherapy Open-label, randomized Phase 2 trial BNT311 as monotherapy and in combination with Pembrolizumab after treatment with SOC immune checkpoint inhibitor B*: BNT311+ pembrolizumab C*: BNT311 + pembrolizumab (alternative treatment schedule) Secondary Endpoints • PFS • DOR Significant unmet need in R/R NSCLC ~1.8 million lung cancer deaths worldwide annually¹ NSCLC is most common type (~85%) ² 5-year survival only 4% for advanced or metastatic. NSCLC3 CPI therapy fails in majority of NSCLC patients due to evolution of resistance Poor prognosis for CPI R/R NSCLC Estimated PFS of < 6 months and OS of <1 year ● New strategies needed to overcome resistance and maximize efficacy Partnered with Genmab; 50:50 profit/loss collaboration R/R, refractory/relapsed; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; SOC, Standard of Care; CPI, check point inhibitor; TPS, tumor proportion score; ORR; objective response rate; PFS, progression free survival; DoR, duration of response; OS, Overall Survival *Following Safety run-in ¹Bray et al., 2018; 2https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics; Cancer statistics, 2018.Siegel et al., CA Cancer J Clin. 2018 Jan; 68(1):7-30 2Qu et al., 2022; https://journals.sagepub.com/doi/10.1177/1758835921992968 BIONTECH Y#21BNT311 & BNT312: Phase 1/2 Expansion Cohorts Ongoing Next Generation Immunomodulators designed to prime & activate anti-tumor T-cell and NK cell function Part 1: Dose Escalation Part 2: Expansion Cohorts 21 GEN 1046/ BNT311 Anti- PD-L1 GEN1042/ BNT312 Anti- CD40 Anti- 4-1BB v Anti- 4-1BB Phase 1/2 Phase 1/2 Expansion dose: 100 mg Expansion dose: 100 mg TNBC 10 expansion cohorts are ongoing NSCLC Urothelial cancer Endometrial cancer HNSCC Cervical cancer n = up to 40 per cohort ● Monotherapy Expansion cohorts. Post-CPI melanoma (MOA) n = up to 22 per cohort • NSCLC • Combination expansion cohorts are currently recruiting Melanoma n = up to 40 per cohort ● BNT311 and BNT312: Programs partnered with Genmab; 50:50 profit/loss collaboration NK cell, natural killer cell; NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer; HNSCC, head and neck squamous cell carcinoma; MoA; mode of action; PDAC pancreatic ductile adenocarcinoma ● PDAC HNSCC BIONTECH Y#22BNT211: CAR-T Cell Program with Potential Targeting Multiple High-Need Solid Tumors 2nd generation CAR-T Directed against CLDN6 Cancer specific carcino- ● ● ● embryonic antigen Expressed in multiple solid. cancers with high medical need CARVac drives in vivo expansion, persistence and efficacy of CAR-T BNT211 CAR Structure 22 extracellular intracellular aCLDN6 scFv CD8 hinge 4-1BB CD3 CLDN6 not present in healthy tissues O CLDN6 expressed in multiple cancers. Patients with CLDN6+ relapsed/ refractory solid tumors (up to 36 patients) High CLDN6 expression CANCER IMMUNOTHERAPY An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Katharina Reinhard¹*, Benjamin Rengstl¹*, Petra Oehm¹*, Kristina Michel¹, Arne Billmeier', Nina Hayduk¹, Oliver Klein¹, Kathrin Kuna¹, Yasmina Ouchan¹, Stefan Wöll¹, Elmar Christ¹, David Weber², Martin Suchan², Thomas Bukur², Matthias Birtel, Veronika Jahndel, Karolina Mroz¹, Kathleen Hobohm², Lena Kranz', Mustafa Diken², Klaus Kühlcke¹, Özlem Türeci¹t, Ugur Sahin ¹,2,3++ Science Part 1 CLDN6 CAR-T dose escalation (3 dose levels) Part 2 CLDN6 CAR-T dose escalation + CLDN6 CARVac CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified; Reinhard K, et al. Science 2020; 367:446-453 RP2D Part 3 Expansion Cohorts ● Ovarian Cancer Testicular Cancer Endometrial Cancer Lung Cancer Gastric Cancer Tumors NOS BIONTECH#23BNT211: CAR-T Engraftment and Tolerable Safety Profile with CLDN6 CAR-T without and with CARVac Cohort/Patient Characteristics Median (range) age, years Cancer type, n Testicular Ovarian Endometrial Fallopian tube Sarcoma Gastric Median (range) CLDN6 II/III+ cells, % Median (range) of prior treatment lines Safety Efficacy 23 ● Part 1 DL1 (n=3) 33 (25-68) 1 0 0 1 0 ● 60 (60-80) 4 (3-5) Part 2 DL1 (n=3) 41 (27-56) 3 0 0 0 0 90 (90-95) 4 (3-4) Part 1 DL2 (n=6) 56 (35-66) CLDN6 CAR-T cells alone or combined with CARVac well tolerated with only 1 DLT observed • CRS grade 1-2 in 1 patient at DL1 + CARVac and 6 patients at DL2, and was manageable by administration of tocilizumab Robust engraftment of CAR-T cells resulting in a total amount of around 10⁹ achieved in most patients and seems predictive for clinical activity ● • 9 of 10 patients showed initial disease control including 4 PRs; 3 in testicular cancer patients with recent relapse after HDCT/ASCT 2 1 1 82.5 (50-90) 5 (2-11) 1 0 1 Part 2 DL2 w/LD (n=2) 53.5 (46-61) 0 2 0 0 0 0 95 (90-100) 6 (5-7) Part 2 DL1 Patient #3 Baseline 12 wks post infusion ⒸO Part 1 DL2 Patient #4 Baseline Part 2 DL2 w/o LD (n=1) 56 6 wks post infusion 30 100OOO 85 4 Data cutoff = NOV 18, 2021; CRS, cytokine release syndrome; DL, dose level; DLT, dose-limiting toxicity; HDCT, high dose chemotherapy; ASCT, autologous stem cell transplant; Haanen J., et al. Oral presentation at the ESMO Immuno-Oncology Congress, December 08-14, 2021; Haanen J. et al. Anals fo Concology (2021) 32 (suppl. 7): S1392-S1397 2 Abstract control #8172, Clinical Trials Plenary Session; will be presented by John Haanen, discussant is Vincent K. Lam, Johns Hopkins University, Baltimore; Session Title: Clinical Trials of Cellular Immunotherapies; Session Date and Time: Sunday Apr 10, 2022 1:31 PM - 1:46 PM; Presentation Number: CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac- mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors All patients (n=15) 54 (25-68) 7 4 1 1 1 1 85 (50-100) 4 (2-11) Upcoming AACR Presentation, April 10th 2 BIONTECH#2424 Agenda 01 Fourth Quarter and Full Year 2021 Highlights Ugur 02 COVID-19 Vaccine Update Özlem Türeci, CMO 03 Oncology Pipeline Update Özlem Türeci, 04 Financial Results Jens Holstein, CFO 05 Corporate Outlook Ryan Richardson, Chief Strategy Officer BIONTECH#25Key Highlights For 2021 Financial Year 25 Total Revenues¹ €19.0 bn Diluted EPS A €39.63 Operating Result Ⓡ €15.3 bn Cash + Cash Deposits and Trade Receivables ·0⁰ €2.1 bn² + €12.4 bn 1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. 2 Includes cash and cash equivalents (€1.7 bn) and cash deposits with an original term of six months which are presented as other financial assets (€0.4 bn). BIONTECH#26Key Highlights For 2021 Financial Year €18.8 bn €14.8 bn €3.0 bn €1.0 bn FY 2021 26 COVID-19 Vaccine Commercial Revenues¹: €18.8 bn Share of gross profit and sales milestones from COVID-19 vaccine sales in the Pfizer and Fosun Pharma territory (100% gross margin) Direct COVID-19 vaccine sales to customers in BioNTech's territory ■COVID-19 Sales to collaboration partners of products manufactured by BioNTech Doses: ~2.6 bn delivered Revenues and margins exceeded expectations 1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. Low- and Middle-Income Countries 40% High-Income Countries 60% BIONTECH#27Key Highlights For 2021 Financial Year 27 Cash Cash and cash equivalents as of December 31, 2021 €1.7 bn Cash Deposits ¹ Cash deposits as of December 31, 2021 €0.4 bn Funds to Finance our Growth² 1 Cash deposit with an original term of six months are presented as other financial assets. 2 Additional influencing factors (i.e. cash outlays) as well as certain collection risk with trade receivables exist. ● Trade Receivables Trade receivables as of December 31, 2021 €12.4 bn BIONTECH#28Comparison Guidance To Actuals 2021 Financial Year COVID-19 vaccine revenues 28 R&D expenses SG&A expenses Capital expenditures Guidance as of Nov 2021 € 16 - 17 bn € 950 1,050 m € 250 - 300 m € 175 - 225 m Actual result FY 2021 € 19 bn € 950 m € 340 m € 180 m Please refer to the Annual Report on Form 20-F for the year ended December 31, 2021 for further details.. HIC, high-income countries ● ● Drivers ~2.6bn doses delivered in 2021 vs. up to 2.5bn doses guided Higher proportion of doses than estimated delivered to HIC -40% related to COVID-19 vaccine clinical program Increase through organic and inorganic growth of organization Investment in infrastructure and COVID-19 vaccine production capacity BIONTECH#29Q4 2021 And FY 2021 Financial Results - Profit or Loss 29 (in millions, except per share data)¹ Research & development revenues Commercial revenues² Total revenues Cost of sales Research and development expenses Sales and marketing expenses General and administrative expenses Other operating income less expenses Operating income / (loss) Finance income less expenses Income taxes Profit / (loss) for the period Earnings per share Basic profit / (loss) for the period per share Diluted profit/ (loss) for the period per share 4Q 2021 €6.6 5,525.9 €5,532.5 (583.2) (271.5) (17.9) (130.9) 170.7 €4,699.7 14.2 (1,547.7) €3,166.2 €12.96 €12.18 1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the consolidated statements of profit or loss has been condensed. 4Q 2020 €65.4 280.0 €345.4 (41.0) (257.0) (6.7) (35.9) 239.4 €244.2 (38.6) 161.3 €366.9 €1.51 €1.43 2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. FY 2021 €102.7 18,874.0 €18,976.7 (2,911.5) (949.2) (50.4) (285.8) 504.0 €15,283.8 (237.4) (4,753.9) €10,292.5 €42.18 €39.63 FY 2020 €178.8 303.5 €482.3 (59.3) (645.0) (14.5) (94.0) 248.1 € (82.4) (63.4) 161.0 €15.2 €0.06 €0.06 BIONTECH#302022 Financial Year Guidance COVID-19 Vaccine Revenues for FY 2022¹ Estimated BioNTech COVID-19 vaccine revenues Planned FY 2022 Expenses and Capex¹ R&D expenses SG&A expenses Capital expenditure Estimated FY 2022 Tax Assumptions BioN Tech Group estimated annual effective income tax rate 30 € 13-17 bn € 1,400 1,500 m M € 450-550 m € 450-550 m -28%² 1 Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions. 2 BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to -28% (FY 2022) due to decreasing average trade tax rates. BIONTECH#31Capital Allocation Framework 31 R&D Activities Accelerate R&D activities in the years to come Corporate and Infrastructure Develop global footprint and invest in manufacturing capabilities for key technologies 1 Based on the shares outstanding as of March 30, 2022 and pending approval at the AGM to be held in June 2022. M&A and Business Development Strengthen technology platforms and digital capabilities by collaborations and potential add-on M&A Return Capital to Shareholders Expect to authorize a share repurchase program of up to $1.5 bn over the next two years. Will propose a special cash dividend of €2.00 per share, aggregate of ~€0.5 bn¹ BIONTECH#3232 Agenda 01 Fourth Quarter and Full Year 2021 Highlights Ugur 02 COVID-19 Vaccine Update Özlem Türeci, CMO 03 Oncology Pipeline Update Özlem Türeci, 04 Financial Results Jens Holstein, CFO 05 Corporate Outlook Ryan Richardson, Chief Strategy Officer BIONTECH#33Outlook for 2022 1 2 3 4 33 O Continued COVID-19 vaccine franchise leadership Further pipeline expansion & acceleration Global footprint & organization Corporate Development Multiple data read-outs expected throughout the year On track to submit regulatory data package for Omicron-adapted vaccine pending decision from regulators Expect data updates for up to 3 additional pipeline programs Global Development Organization transformation underway to support pipeline expansion and potential initiation of registration trials Expanding footprint in Europe, U.S., Asia, and Africal Investing to expand global mRNA manufacturing capacity with new production nodes - including deployment of our first BioN Tainer New partnerships & M&A to accelerate and enable long-term strategy Extend mRNA platform into new "white spaces" and further expand toolkit in synthetic biology following collaborations with Medigene and Crescendo BIONTECH#34Expected Pipeline Milestones in 2022 (1 of 2) BNT162b2 • Data for 4th dose in adults, aged 16 to 65 years Data for 3rd dose in children, aged 5 to <12 years Data for 3-dose regimen in children, aged 6 months to <5 years ● ● Next-Generation COVID-19 vaccines • Data for Omicron-based vaccine (monovalent) Multiple updates: Variant combinations and bivalent vaccines ● 8+ Data Updates Other pipeline programs BNT 161 - Influenza mRNA vaccine ¹ BNT1222 Phase 2 - iNeST in combination w/Pembrolizumab, 1L Melanoma BNT211 Phase 1/2 CAR-T/CLDN6+, multiple solid tumors 34 CLDN, Claudin; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer 2 Partnered with Genentech Timing ongoing ongoing April April 2H 1H 2H 2H BIONTECH#35Expected Pipeline Milestones in 2022 (2 of 2) Infectious Diseases • Shingles vaccine ¹ ● Tuberculosis vaccine2 HSV 2 vaccine Malaria vaccine ● ● Oncology BNT141 - RiboMab, solid tumors. • BNT142 - RiboMab, solid tumors BNT116 - Fixvac in combination w/Libtayo, NSCLC ● Up to 7 First-in-Human Trial Starts 35 HSV 2, herpes simplex virus type 2; FPD, first patient dosed; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer 2 Partnered with Bill and Melinda Gates Foundation Timing 2H 2H 2H 2H ✓ FPD in January 1H 2H BIONTECH#36SAVE THE DATE BIONTECH Annual General Meeting June 1, 2022 Capital Markets Day June 29, 2022 36 BION ECH PDE BIO#37THANK YOU BIONTECH